Skip to content

Effect of Aniseed in treatment of gastrointestinal symptoms in Coronavirus disease

Efficacy of Aniseed powder formulation (Aniseed Safoof) to improve gastrointestinal symptoms in COVID-19 patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120506009651N3
Enrollment
225
Registered
2022-04-04
Start date
2022-03-26
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 infection. Covid-19, confirmed cases, positive test result

Interventions

Intervention 1: Intervention group: Anise edible powder or anise safoof is a combination of anise fruit powder and candy powder. The method of preparation of this drug form is by grinding & sieving te

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients from 18 years old to 70 years old with a diagnosis of Coronavirus based on clinical and laboratory symptoms; hospitalization, home quarantine and outpatients Diarrhea, anorexia, nausea or vomiting and abdominal pain within 24-48 hr

Exclusion criteria

Exclusion criteria: Pregnant or nursing females Organic disorders with survival time of less than 3 days Significant allergic reactions to the herbal drug

Design outcomes

Primary

MeasureTime frame
Diarrhea. Timepoint: Before and after intervention. Method of measurement: Visual analogue scale (VAS) questionnaire which graded from zero (no sign) to 10 (severe sign).;Anorexia. Timepoint: Before and after intervention. Method of measurement: Visual analogue scale (VAS) questionnaire which graded from zero (no sign) to 10 (severe sign).;Abdominal pain. Timepoint: Before and after intervention. Method of measurement: Visual analogue scale (VAS) questionnaire which graded from zero (no sign) to 10 (severe sign).

Secondary

MeasureTime frame
Gastrointestinal disorders. Timepoint: End of Treatment (2 weeks after starting intervention). Method of measurement: Visual analogue scale (VAS) questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Pasalar

Shiraz University of Medical Sciences

pasalar@sums.ac.ir009832084029

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026